BiotechTube

Enzalutamide + Goserelin acetate + Leuprolide acetate

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adenocarcinoma of the Prostate

Conditions

Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer

Trial Timeline

Apr 2, 2014 → Jan 1, 2040

NCT ID
NCT02023463

About Enzalutamide + Goserelin acetate + Leuprolide acetate

Enzalutamide + Goserelin acetate + Leuprolide acetate is a phase 1 stage product being developed by Astellas Pharma for Adenocarcinoma of the Prostate. The current trial status is active. This product is registered under clinical trial identifier NCT02023463. Target conditions include Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer.

What happened to similar drugs?

1 of 20 similar drugs in Adenocarcinoma of the Prostate were approved

Approved (1) Terminated (0) Active (19)
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
🔄Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
🔄CT-P16 + AvastinCelltrionPhase 3
🔄Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3
🔄Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
6
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02023463Phase 1Active

Competing Products

20 competing products in Adenocarcinoma of the Prostate

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
ACR-368 + GemcitabineAcrivon TherapeuticsPhase 2
32
RamucirumabEli LillyPhase 1/2
32
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
40
BA3182BioAtlaPhase 1
26
Ramucirumab (IMC-1121B ) + PaclitaxelEli LillyPhase 1
29
CT-P16 + AvastinCelltrionPhase 3
40
Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3
40
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
44
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
42
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
DS-8201aDaiichi SankyoPhase 1
29
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
39
EnzalutamideAstellas PharmaPhase 2
35
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44